AI-generated analysis. Always verify with the original filing.
Fortress Biotech reported improved 2025 financial results with reduced net loss and announced significant corporate transactions, including the FDA approval of ZYCUBO® for Menkes disease and the $205 million sale of a Priority Review Voucher.
Event Type
Disclosure
Mandatory
Variant
8-K
.** **Results of Operations and Financial Condition****.** On March 31, 2026, Fortress Biotech, Inc. issued a press release to provide a corporate update and
.** **Financial Statements and Exhibits****.** (d) Exhibits. The following exhibit is furnished herewith: | 99 | | | |---|---|---| | Exhibit Number | |
| Metric | Value | Basis |
|---|---|---|
| Consolidated Net Revenue | $63.30 | |
| Consolidated Research and Development Expenses | $11.90 | |
| Consolidated Selling, General and Administrative Costs | $96.40 | |
| Consolidated Net Loss Attributable to Common Stockholders | $-1.90 | |
| Diluted EPS | $-0.07 |